Market openNon-fractional
AnaptysBio/ANAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About AnaptysBio
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Ticker
ANAB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
117
Website
www.anaptysbio.com
AnaptysBio Metrics
BasicAdvanced
$680M
Market cap
-
P/E ratio
-$6.13
EPS
-0.31
Beta
-
Dividend rate
Price and volume
Market cap
$680M
Beta
-0.31
Financial strength
Current ratio
11.531
Quick ratio
11.201
Long term debt to equity
681.818
Total debt to equity
685.613
Interest coverage (TTM)
-7.72%
Management effectiveness
Return on assets (TTM)
-20.22%
Return on equity (TTM)
-136.73%
Valuation
Price to revenue (TTM)
28.884
Price to book
14.4
Price to tangible book (TTM)
14.4
Price to free cash flow (TTM)
-4.944
Growth
Revenue change (TTM)
114.78%
Earnings per share change (TTM)
26.65%
3-year revenue growth
-31.44%
3-year earnings per share growth
77.79%
What the Analysts think about AnaptysBio
Analyst Ratings
Majority rating from 11 analysts.
AnaptysBio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.1M
-21.11%
Net income
-$44M
4.03%
Profit margin
-618.30%
31.87%
AnaptysBio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.50
-$1.41
-$1.59
-$1.64
-
Expected
-$1.70
-$1.79
-$1.60
-$1.57
-$0.89
Surprise
-11.63%
-21.40%
-0.70%
4.75%
-
AnaptysBio News
AllArticlesVideos
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
GlobeNewsWire·2 months ago
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AnaptysBio stock?
AnaptysBio (ANAB) has a market cap of $680M as of July 05, 2024.
What is the P/E ratio for AnaptysBio stock?
The price to earnings (P/E) ratio for AnaptysBio (ANAB) stock is 0 as of July 05, 2024.
Does AnaptysBio stock pay dividends?
No, AnaptysBio (ANAB) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next AnaptysBio dividend payment date?
AnaptysBio (ANAB) stock does not pay dividends to its shareholders.
What is the beta indicator for AnaptysBio?
AnaptysBio (ANAB) has a beta rating of -0.31. This means that it has an inverse relation to market volatility.
Buy or sell AnaptysBio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.